| HOME >> BIOLOGY >> TECHNOLOGY |
SAN RAMON, Calif., June 2 /PRNewswire/ -- BioGenex, a developer of innovative instruments and reagents for automated slide based staining systems for molecular diagnostics, announced today that Abbott has entered into a definitive agreement to extend the technology co-development and distribution agreement to market the Xmatrx(R) platform for the automation of Abbott's extensive FISH product line. Under the terms of the agreement Abbott customers will have the option to run IHC and ISH on the Xmatrx and BioGenex customers to run FISH on their system.
"We are extremely pleased that Abbott has chosen to renew our relationship with this multi-year extension of our original agreement. This is a testament to the truly unique capabilities of the Xmatrx(R) platform, which allows for the automation of advanced molecular staining assays, from Microtome to Microscope," said Dr. Krishan Kalra, CEO, BioGenex. "We look forward to furthering our partnership and delivering solutions that can further accelerate the adoption of molecular medicine approaches from drug discovery through clinical diagnostics."
The Xmatrx(R) platform allows for the walk-away automation of the entire FISH assay workflow, from specimen pretreatment to final cover-slipping and is designed for optimal results with Abbott Molecular AutoFISH(TM) reagents and FISH technology.
The Xmatrx will be co-branded and marketed under a co-exclusive distribution agreement which calls for both parties to collaborate further in aiding adoption of FISH, IHC and ISH as primary tools in the emerging field of molecular diagnostics and personalized medicine. Under the terms of the agreement BioGenex will receive a multi-year minimum volume commitment from Abbott.
About Xmatrx
The Xmatrx(R) is an integrated system consisting of a flexible intelligent platform capable of full automation from "Microtome to Microscope" for any slide b
'/>"/>
| SOURCE BioGenex Copyright©2009 PR Newswire. All rights reserved |